Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy

被引：13

作者：

Gamble, Lena J. ^{[1
,2
,3
,4
]}

Borovjagin, Anton V. ^{[5
]}

Matthews, Qiana L. ^{[1
,2
,3
,4
,6
]}

机构：

[1] Univ Alabama Birmingham, Dept Med, Div Human Gene Therapy, Gene Therapy Ctr, Birmingham, AL 35294 USA

[2] Univ Alabama Birmingham, Dept Pathol, Div Human Gene Therapy, Gene Therapy Ctr, Birmingham, AL 35294 USA

[3] Univ Alabama Birmingham, Dept Surg, Div Human Gene Therapy, Gene Therapy Ctr, Birmingham, AL 35294 USA

[4] Univ Alabama Birmingham, Dept Obstet & Gynecol, Div Human Gene Therapy, Gene Therapy Ctr, Birmingham, AL 35294 USA

[5] Univ Alabama Birmingham, Sch Dent, Inst Oral Hlth Res, Birmingham, AL 35294 USA

[6] Univ Alabama Birmingham, Ctr AIDS Res, Birmingham, AL USA

来源：

EXPERIMENTAL AND THERAPEUTIC MEDICINE | 2010年 / 1卷 / 02期

关键词：

targeted therapy; integrin; arginine-glycine-aspartate; ovarian cancer; adenovirus; virotherapy; MEDIATED GENE-TRANSFER; COXSACKIEVIRUS-ADENOVIRUS RECEPTOR; HUMAN-MELANOMA CELLS; ALPHA-V INTEGRINS; IN-VIVO; ALPHA(V)BETA(3) INTEGRIN; ENHANCED INFECTIVITY; GLIOMA-CELLS; PHASE-I; ALPHA-V-BETA-3; INTEGRIN;

D O I：

10.3892/etm_00000037

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The purpose of this article was to review the current strategies of targeted therapy to integrins and define the best course of future research in ovarian cancer targeting. Cell surface integrin targeting has been used as a strategy for targeted therapy of several diseases with some success. The combination of virotherapy and integrin-targeting shows promise as a method for targeting ovarian cancer. More specifically, targeting of ovarian cancer with integrin-directed adenoviruses may lead to therapy with fewer toxicities and side effects. This article offers a review of the benefits of integrin-specific targeted therapy for several diseases and proposes a unique anti-ovarian cancer strategy involving the combination of the above with virotherapy as a potential anti-ovarian cancer treatment.

引用

页码：233 / 240

页数：8

共 122 条

[1]

ALBELDA SM, 1990, CANCER RES, V50, P6757

[2] CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors [J].

Alemany, R ;

Curiel, DT .

GENE THERAPY, 2001, 8 (17) :1347-1353

[3] A phase I study of recombinant adenovirus vector-mediated delivery of an Anti-erbB-2 single-chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients [J].

Alvarez, RD ;

Curiel, DT .

HUMAN GENE THERAPY, 1997, 8 (02) :229-242

[4]

Alvarez RD, 2000, CLIN CANCER RES, V6, P3081

[5] Adenoviral-mediated suicide gene therapy for ovarian cancer [J].

Alvarez, RD ;

Gomez-Navarro, J ;

Wang, MH ;

Barnes, MN ;

Strong, TV ;

Arani, RB ;

Arafat, W ;

Hughes, JV ;

Siegal, GP ;

Curiel, DT .

MOLECULAR THERAPY, 2000, 2 (05) :524-530

[6] Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [J].

Arap, W ;

Pasqualini, R ;

Ruoslahti, E .

SCIENCE, 1998, 279 (5349) :377-380

[7] Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].

Armstrong, DK ;

Bundy, B ;

Wenzel, L ;

Huang, HQ ;

Baergen, R ;

Lele, S ;

Copeland, LJ ;

Walker, JL ;

Burger, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43

[8] Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor [J].

Asaoka, K ;

Tada, M ;

Sawamura, Y ;

Ikeda, J ;

Abe, H .

JOURNAL OF NEUROSURGERY, 2000, 92 (06) :1002-1008

[9] MUTATIONS THAT ALTER AN ARG-GLY-ASP (RGD) SEQUENCE IN THE ADENOVIRUS TYPE-2 PENTON BASE PROTEIN ABOLISH ITS CELL-ROUNDING ACTIVITY AND DELAY VIRUS REPRODUCTION IN FLAT CELLS [J].

BAI, M ;

HARFE, B ;

FREIMUTH, P .

JOURNAL OF VIROLOGY, 1993, 67 (09) :5198-5205

[10]

Barnes MN, 2002, MOL CANCER THER, V1, P435

← 1 2 3 4 5 6 7 8 9 10 →